The homework stays closed on the desk. A ten-year-old boy flips it open and shuts it again, then his eyes drift to a toy in the corner. Twenty minutes pass and the vocabulary list is still untouched. For his parents, the pattern was a slow spiral of tutors, scolding, and guilt — until a small device on his forehead turned focus into a video game he actually wanted to win.
That device is now a registered medical product. BrainCo (强脑科技) has launched the medical version of "Zhuanzhu Xin" (专注欣), an ADHD intervention built on a non-invasive brain-computer interface (脑机接口). Both halves of the system — the attention-deficit/hyperactivity training software and a single-channel forehead EEG sensor — have obtained China's Class II medical-device registration certificate.
What actually got cleared
The hardware is deliberately unglamorous: a lightweight, front-cortex EEG pickup that is easier to wear than the wired caps used in clinics. The software sets children tasks inside game-like scenes. When the wearer concentrates, the on-screen character speeds up or earns a reward; when attention drifts, it slows or stalls. The loop trains the child to notice and steer their own brain state.
BrainCo says a daily session runs about 25 minutes. The child keeps the device on, opens the software, and completes the game-driven tasks; the system then auto-generates a report for doctors and parents to track. The certificate covers both the software and the sensor as a medical-device pairing, which the company frames as the first full hardware-plus-software medical certification for BCI-based ADHD intervention in the children's neuro-rehabilitation space.
How neurofeedback training works
The underlying idea is not new. Children with ADHD commonly show elevated theta waves and reduced beta waves — an electrical rhythm linked to the wandering attention parents see every evening. A neurofeedback headband reads those waves in real time and turns them into a visible score or animation. The child is rewarded for pushing the ratio the right way, and over repeated sessions learns, consciously at first and then automatically, to hold a focused state.
What BrainCo adds is the gamification and the medical-grade packaging. Jin Xingming, a lifetime professor at Shanghai Children's Medical Center and a founder of Chinese developmental-behavioral pediatrics, has presented clinical work built on the Zhuanzhu Xin system. She argues non-invasive BCI is a drug-free adjunct that can improve attention, self-control, and executive function, and that combining it with medication showed stronger results in controlled comparisons — with notably better outcomes in the 6–7 age group.
The ADHD numbers behind the market
ADHD is among the most common neurodevelopmental disorders of childhood. A 2021 national epidemiological survey of Chinese children and adolescents put the prevalence at roughly 6.4 percent, which media reporting translates to around 23 million affected young people. That is the pool BrainCo and a growing field of Chinese neurofeedback startups are targeting — families looking for something other than, or in addition to, medication.
The broader signal is policy momentum. In March 2026 "brain-computer interface" was written into China's Government Work Report for the first time, named alongside future-energy, quantum tech, embodied AI, and 6G as a future industry to cultivate. That framing pulls neurofeedback out of the wellness-gadget corner and into regulated medical development.
According to Li An, chief scientist at BrainNet (脑机网), a Class II clearance converts neurofeedback from a consumer wellness tool into a clinically governed one — but he stresses parents should treat it as an adjunct, not a substitute for proper diagnosis and care.
Reading the signal beyond the certificate
A clearance like this is best read as permission to study and deploy a product under oversight, not as a verdict on how well it works. For families, the practical meaning is narrower than the marketing language suggests: a regulated, traceable option now sits on the table alongside the older defaults of medication and behavioral therapy. The interesting shift is cultural as much as medical. When attention training is packaged as a game a child volunteers to play, the daily friction of "sit down and focus" can soften into something cooperative. That alone can lower the household stress that surrounds every ADHD diagnosis, even before anyone measures whether the brain waves themselves moved.
What the policy spotlight adds is momentum for the whole category. With brain-computer interface named a future industry, more clinics, insurers, and school systems may start taking non-invasive neurofeedback seriously enough to fund the larger trials that today's evidence still lacks. Parents gain, at minimum, a steadier framework for asking the right questions rather than chasing the loudest claim.
Honest limitations
- A Class II certificate confirms the device is safe and functionally registered; it is not the same as proof that it outperforms medication or behaves as a cure.
- Reported benefits come from the company's and affiliated clinicians' presentations, not yet from independently published, large randomized trials.
- Neurofeedback trains self-regulation skill; effects depend heavily on adherence, age, and whether the child also receives behavioral and educational support.
- The 6.4 percent prevalence and 23-million estimate derive from a single 2021 national survey cited in media, not a fresh double-count here.
- The system is positioned for ages 6–12; evidence and labeling for older or adult ADHD are not part of this clearance.
What readers can do now
- If a child shows persistent inattention or impulsivity, get a proper clinical diagnosis first — a device is not a shortcut to that step.
- Ask any provider claiming "BCI ADHD training" whether the product holds a valid NMPA (国家药监局) medical-device registration, not just a fitness-app label.
- Treat neurofeedback as one tool in a plan that may include behavioral therapy and, where appropriate, medication discussed with a pediatrician.